Immutep Limited reported a net loss of A$79.3 million for the year ended 30 June 2026, an increase from A$61.4 million in the prior period, driven by higher R&D expenses and clinical trial costs. The company recognized A$14.6 million in revenue from its licensing partner Dr Reddy’s Laboratories, following a US$20 million upfront payment received in January 2026 and a subsequent US$10 million repayment in June 2026 after the discontinuation of the pivotal TACTI-004 Phase III trial for non-small cell lung cancer. The company ended the period with A$68.9 million in cash and expects its runway to extend into the first half of calendar year 2028. Additionally, Nasdaq notified Immutep that its American Depositary Shares no longer comply with the $1.00 minimum bid price requirement, granting an 180-day compliance period expiring on October 26, 2026. The company operates in the biotechnology industry, developing LAG-3 related immunotherapies for cancer and autoimmune diseases.

Immutep reported positive mature overall survival data from the INSIGHT-003 clinical trial in first-line non-small cell lung cancer (NSCLC). The company also provided an update regarding the TACTI-004 clinical trial. Immutep is a biotechnology company focused on developing immunotherapy treatments.

Immutep Limited announced that it will present positive interim Phase I data for its first-in-class LAG-3 agonist antibody, IMP761, at the EULAR 2026 conference. No specific financial or clinical figures were provided in the filing.